Bleomycin-Induced Hypertrophic Scarring animal model in Mice

Introduction :

Hypertrophic scarring is a challenging condition characterized by excessive collagen deposition and tissue fibrosis, often occurring as a result of injuries or surgical procedures. Bleomycin-induced hypertrophic scarring in mice serves as a valuable model for studying potential therapies and interventions. In this blog post, we delve into the methodology and significance of such research, emphasizing the importance of ethical considerations and robust experimental design.

Procedure :

Bleomycin, a known inducer of fibrosis, is administered via daily subcutaneous injections into the dorsum of mice for a period of 28-56 days. This prolonged exposure mimics the chronic nature of hypertrophic scarring. Treatment with test compounds commences 7 days post-Bleomycin administration, allowing for the assessment of their therapeutic effects on established fibrotic lesions.

Efficacy Readout

Several parameters are evaluated to gauge the efficacy of the test compounds:

Body weights: Changes in body weight serve as a general indicator of overall health and response to treatment.

Histopathology of skin and lung: Detailed microscopic examination of tissue sections provides insights into the extent of fibrosis, inflammatory infiltrates, and tissue remodeling.

Collagen content in skin: Biochemical assays are employed to quantify collagen levels, a key hallmark of fibrotic tissue.


Statistical analysis is performed using one-way ANOVA with a 95% confidence level, allowing for the comparison of multiple treatment groups and control. This rigorous statistical approach ensures the reliability and validity of the experimental findings.

Clinical Observations:

In addition to the quantitative assessments, general clinical signs are closely monitored throughout the study, including behavior, appearance, and any adverse reactions to treatment.


The utilization of the Bleomycin-induced hypertrophic scarring model in mice offers a valuable platform for evaluating novel therapeutic interventions aimed at mitigating fibrosis. By adhering to ethical guidelines and employing robust experimental methodologies, researchers can contribute to the advancement of treatments for hypertrophic scarring, ultimately improving patient outcomes and quality of life.

This blog post highlights the interdisciplinary nature of preclinical research, bridging the fields of animal science, pharmacology, and dermatology in pursuit of innovative solutions to complex medical conditions.

  • 1. Mahesh Kumar R S – Associate Director Biology at TheraIndx Lifesciences